Showing posts with label medical innovation. Show all posts
Showing posts with label medical innovation. Show all posts

Thursday, June 6, 2013

New healthcare model cut even more costs in year two:

NEW YORK | Thu Jun 6, 2013 8:10am EDT
(Reuters) - The nation's largest experiment in delivering medical care in an innovative way has reduced costs and improved the quality of care even more in its second year than in its first, according to the insurance company behind it.
The nonprofit CareFirst BlueCross BlueShield launched its "Patient-Centered Medical Home" program in January 2011 among primary-care providers serving about one-third of its 3.4 million members in Maryland, Washington, D.C., and northern Virginia.
Like other "accountable care organizations" (ACOs), which are centerpieces of President Barack Obama's healthcare reform, the medical home program ties insurance payments to healthcare providers to the quality of care they deliver.
On Thursday, CareFirst reported cost savings of $98 million for the medical home program in 2012, compared with $38 million the year before. Proponents of the model say it shows that "bending the cost curve downward," as Obama described one of the goals of his 2010 healthcare law, is achievable. If innovative models like CareFirst's deliver as promised, it will ease the financial pressures on Medicare, the government health insurance program for the elderly and disabled, and make Obama's healthcare reform more likely to succeed.
"This is a very important finding, that a major health plan is able to achieve savings" of this magnitude, said Dr Elliott Fisher, a health policy expert at the Dartmouth Institute for Health Policy and Clinical Practice and an architect of accountable care organizations.
Medical homes, like other ACOs, induce physicians to coordinate care to make sure patients' prescriptions don't interact adversely, for instance, and to think twice before ordering unnecessary tests. Physicians who reduce costs while hitting quality metrics such as regularly checking a diabetic's eyesight receive awards in the form of higher payments.
In CareFirst's program, that incentive is substantial: a 29 percent bump in physician reimbursement rates. The insurer can afford to be so generous because improving primary care, which accounts for only 6 percent of medical spending, reduces far pricier hospitalizations and specialist visits.
CareFirst's success is likely to accelerate other efforts to move from a traditional fee-for-service model, where the more tests and treatments physicians and hospitals do the more they make, to one that rewards efficiency and quality. Twenty-nine U.S. states now let primary-care providers act as patient-centered medical homes for residents on the Medicaid program for the poor, for instance.
Major insurers including UnitedHealth Group, WellPoint, Aetna, Humana and Cigna are also contracting with physicians to operate under an accountable care model.
BUILDING UP SAVINGS
Skeptics have warned that any savings in programs like medical homes would peter out after their first year, as physicians eliminated the most obvious and easiest-to-cut waste, and that further reductions would cut necessary care.
CareFirst has found otherwise.
One million of its members (almost all employed, with an average age of 42) were in medical homes in 2012, the company reported, and 80 percent of the primary-care providers in CareFirst's network participate in the program. These members' healthcare costs were $98 million (2.7 percent) less than CareFirst projected. In 2011, the savings were 1.5 percent.
Most of the savings came from reduced hospital admissions, less use of emergency rooms and lower spending on drugs, said CareFirst Chief Executive Officer Chet Burrell.
Two-thirds of the 3,600 physicians and nurse practitioners participating in the medical home program earned higher reimbursements from CareFirst in 2012, based on a combination of cost savings (which averaged 4.7 percent) and quality measures. Measuring quality - which also includes having extended office hours and using electronic medical records - keeps doctors from trying to save money by skimping on needed care.
"This is a measurable and meaningful step in the right direction of slowing the rise of healthcare costs," said Burrell.
At primary-care practices that did not earn an incentive award, costs averaged 3.6 percent higher than expected. Their quality scores were also worse, suggesting that wasteful care often goes hand in hand with poor care.
CareFirst's savings are in line with those reported by 10 physician groups across the United States that treated Medicare patients under an accountable care model. Annual savings averaged $114 per patient, researchers led by Fisher reported in the Journal of the American Medical Association last year. But savings reached $532, or 5 percent, for patients eligible for both Medicare and Medicaid.
CareFirst received a grant from the federal Centers for Medicare and Medicaid Services to expand the medical home model to Medicare patients starting July 1. These older Americans "frequently have complex health needs and multiple chronic health conditions," said Burrell, and so "could benefit greatly from the coordinated model of care" in medical homes.

(Reporting by Sharon Begley and Caroline Humer; Editing by Douglas Royalty)

Sunday, June 2, 2013

Medicine looks to industries for inspiration




 Connected coverage — selected articles on trends, challenges and controversies in the changing world of medicine.

Posted April 22, 2013
When physicians, hospitals and health systems encounter systemic problems that might lead to inefficient or substandard patient care, they don't always look within to find solutions. In some cases, the ways that nonmedical industries have changed their practices to boost quality, safety or efficiency can provide valuable examples that doctors and other health professionals can adapt to their own situations.
American Medical News has shed light on several instances in which the medical system has borrowed expertise and best practices developed by experts in other occupations that at first glance might appear to be completely unrelated. It might come as a surprise that the lessons learned by professionals overseeing car assembly lines, racing vehicle pit lanes and airplane cockpits can be used to improve medical care. Although they are not perfect analogies, champions of the approaches say the evidence is clear that adapting these solutions thoughtfully can save time, money and lives.

Cardiac treatment improves after taking page from Toyota playbook

The use of “lean management” principles, which focus on boosting productivity through reducing variation and waste, helped make the Toyota Motor Corp. the world's largest automobile manufacturer. New research shows that the principles also are working for hospital interventional cardiac care units, where lean management has entailed standardized admission order sets, immediate alerts for cardiac catheterization teams and regular monitoring of clinical procedures.

Doctors use Formula One pit crews as safety model

Racing pit crews help their drivers shave valuable seconds off their times through precision and near-perfect synchronization, with the overarching goal of keeping everyone at the track safe in the process. Following the crews' example, U.S. and British hospitals use similar elements of team leadership, situational awareness and data checklists to cut down on the rates of potentially harmful errors when handing off surgery patients to recovery settings.

Patient safety: What can medicine learn from aviation?

Many believe aviation safety principles such as adherence to checklists, crew resource management and anonymous incident reporting hold great potential for adaptation to the field of medicine — and in some ways they already have been adapted. But some experts caution that patients are not airplanes, and attempting to copy aviation's example without applying those skills to a particular process of medical care will not necessarily yield the results that everyone wants.

ENTREVESTOR: Exploring medical innovation

May 15, 2013 - 6:20pm BY PETER MOREIRA | ENTREVESTOR
In the midst of interviewing ABK Biomedical’s new CEO Pat O’Connor on the Halifax company’s direction, I realized that the story I should write was about O’Connor himself.
Last October, the company announced it had raised $1.25 million in funding from a variety of sources, and co-founder and chief scientific officer Daniel Boyd said, almost parenthetically, that it had also hired a new chief executive from Ireland, a man called Pat O’Connor, a former executive with Boston Scientific Corporation, a worldwide developer, manufacturer and marketer of medical devices.
When I finally interviewed him this month, I was astonished by his savvy and industry knowledge as he explained that ABK is at a critical juncture. The company, which is mainly focused on treating uterine fibroids, or benign tumours in a woman’s uterus, is now completing important development testing in preparation for applying for regulatory approval in Europe, the U.S. and/or Canada.
With the support of Springboard Atlantic, an organization that aids commercialization of university research, ABK a few years ago developed OccluRad — tiny bio-compatible glass beads that can treat uterine fibroids. About 40 per cent of women over 35 worldwide develop these tumours, and many require a hysterectomy. Yet radiologists are now tackling this problem in a minimally invasive manner by injecting beads into a target area and essentially blocking the area around the fibroid and starving it of blood.
The problem is that the beads now used in this procedure aren’t visible under fluoroscopy (an imaging technique that uses X-rays to obtain real-time moving images), so the radiologists have to introduce a dye that is visible to confirm that the right blood vessels are blocked.
ABK Biomedical’s innovation is the development of new particles, or to use the clinical term, radiopaque embolic beads, that are visible under fluoroscopy so the dye is no longer needed. That reduces costs, makes the procedure quicker and eliminates the risk of a toxic reaction from the dye.
O’Connor explained that the company now has its corporate structure in place, has lined up manufacturers and partners and is now assessing where it should first seek regulatory approval. The options being assessed are the U.S., Canada and the European Union, or any combination of the three.
The company will begin design verification testing, which includes such things as pre-clinical study, bio-compatibility testing and design verification bench testing, in August, for completion around January 2014.
Preliminary indications reveal the company may be able to receive approval for some applications with rigorous pre-clinical tests rather than full clinical trials. That means regulatory approval in whatever market it chooses first could come in mid-2014.
However, O’Connor added that that does not mean the company won’t proceed with clinical trials later in 2014 — depending on a couple of factors. “Even if you don’t need it (a clinical trial) for regulatory approval, it’s very powerful in gaining market approval,” said O’Connor. Also, patients with uterine fibroids are otherwise healthy and this will drive the requirement for ABK to generate clinical data for regulatory approval in some regions.
What O’Connor was displaying was a knowledge of the medical device development understood by few people — if any — in the Halifax medical device community. For example, when we discussed the continuing research that Boyd and his team was doing at Dalhousie University, and how this could lead to new products, O’Connor explained the challenges of bringing a product from the R&D stage to the market. These include not only safety and efficacy, but the market opportunity, the routes to market, the cost of making the product and what price it could bring in.
The trick, therefore, is not just to develop a device that improves health outcomes and is safe, but also one that can be manufactured and sold with acceptable margins. Any technology selected for development within ABK will be assessed with all those factors in mind.
O’Connor, who has worked for such medical device giants as Boston Scientific and Stryker Orthopaedics, is happy to share his knowledge with others in the medical device community. He hopes to be involved in a biotech mentoring session to be held by Springboard Atlantic and First Angel Network, June 12 and 13, at the Innovacorp Enterprise Centre in Halifax.